Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...

WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...

Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...

Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...

Addressing stigma, inequity, and access to HIV innovations remains critical to progress in the global HIV response, says IAS ...

(MENAFN- Caribbean News Global) GENEVA, Switzerland – WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable lenacapavir as pre ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees ...

In Donald Trump’s 2019 State of the Union Address, he made “a commitment to eliminate the HIV epidemic in the United States ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for ...

The Dow Jones Industrial Average lost 696.75 points, or 1.63%, to close at 41,938.45. The S&P 500 slid 1.54% to 5,827.04, ...